Pronóstico del mercado de radiofármacos de Asia Pacífico hasta 2028: impacto de COVID-19 y análisis regional por tipo (medicina nuclear de diagnóstico y medicina nuclear terapéutica), aplicación (oncología, cardiología, neurología y otras) y usuario final (hospitales, centros de imágenes, centros académicos y Centros de Investigación, y Otros)
Introducción al mercado
APAC está formado por cinco países principales: China, Japón, India, Australia y Corea del Sur. El mercado también se evalúa para el resto de países de Asia Pacífico. Japón lideró el mercado durante el período previsto. Durante los últimos años, Japón ha ido aumentando su atención hacia el campo de la medicina nuclear. Japón ha entrado en la era de la población geriátrica de más rápido crecimiento; El creciente envejecimiento de la población ha llevado a la transformación de los sistemas médicos. Por ejemplo, según el Foro Económico Mundial, actualmente hay 2.300 millones de personas de 70 años en Japón. La avanzada transición sanitaria se percibe en el país y presiona cada vez más la sostenibilidad de sus sistemas de salud. El aumento de la población geriátrica es responsable del aumento de la carga de enfermedades en la región. Las organizaciones gubernamentales y los institutos de investigación participan en la fabricación de radiofármacos. Por ejemplo, el Departamento de Desarrollo de Radiofármacos, que forma parte del Instituto Nacional de Ciencias Radiológicas, tiene como objetivo desarrollar radiofármacos que sean útiles para el diagnóstico y tratamiento clínico, desarrollar nuevos radionucleidos necesarios para sintetizar medicamentos y fabricar técnicas de etiquetado. El crecimiento vertiginoso en los países emergentes y el creciente uso de medicamentos nucleares para tratamientos personalizados son el principal factor que impulsa el crecimiento del mercado de radiofármacos de APAC.
En el caso de COVID-19, APAC se ve muy afectado, especialmente India. Las prácticas médicas en la región continúan adaptándose a los desafíos del COVID-19. Por un lado, los profesionales de la salud están respondiendo a la pandemia y, por otro, garantizan una interrupción mínima de los procedimientos y hospitalizaciones no relacionados con la COVID. Los hospitales y otros centros sanitarios de todo el mundo se ven obligados a posponer procedimientos electivos, como las cirugías. La mayoría de las terapias no urgentes se han pospuesto. La pandemia de COVID-19 afectó a los servicios de atención médica en muchas dimensiones, empezando por la interrupción del flujo regular de pacientes a los centros de atención médica, el estrés y la sobrecarga de los recursos de atención médica y la implementación de medidas de protección adicionales y distanciamiento social con una mayor utilización de Telesalud y medicina virtual. Como enfoque de precaución, los consultorios de oncología implementaron medidas específicas para reducir la cantidad de pacientes en clínicas ambulatorias, reducir los procedimientos innecesarios o electivos y dar de alta a los pacientes de los servicios de internación. Esto ha impactado negativamente el crecimiento del mercado de radiofármacos en la región. Además, los actores del mercado también se han visto afectados por la pandemia debido a los contrarios en la cadena de suministro y la reducción de la demanda. El segmento de especialidad farmacéutica, especialmente el de radiofarmacia, se vio afectado debido al COVID-19 y la competencia en radiofarmacia. Incluso antes de la pandemia, la cadena de suministro de la Medicina Nuclear era muy compleja y dependía de la disponibilidad de materias primas, las operaciones de las instalaciones de fabricación y la confiabilidad del transporte aéreo. Por lo tanto, los factores mencionados anteriormente están impactando negativamente el mercado de radiofármacos en la región.
Visión general y dinámica del mercado
Se espera que el mercado de radiofármacos de APAC crezca de 1.384,59 millones de dólares en 2021 a 2.661,38 millones de dólares en 2028; se estima que crecerá a una tasa compuesta anual del 9,8% de 2021 a 2028. La terapia alfa dirigida (TAT) es la técnica más reciente y en evolución utilizada para el tratamiento del cáncer local y sistémico. Las investigaciones preclínicas y los ensayos clínicos demuestran que los radionucleidos emisores alfa matan las células cancerosas específicas y no dañan las células sanas (citotoxicidad selectiva). 211At, 213Bi, 225Ac y 227Th se encuentran entre los radioisótopos emisores alfa utilizados para marcar vectores dirigidos como anticuerpos monoclonales; Los anticuerpos monoclonales marcados con radionúclidos emisores de α se están perfilando como una radioinmunoterapia eficaz. Los radioisótopos (partículas α) de alcance más corto se utilizan para tratar pacientes con cáncer hematológico. Las radiaciones alfa son adecuadas para matar células cancerosas aisladas en los sistemas vascular y linfático, así como para hacer retroceder tumores al alterar las redes capilares tumorales para atacar y matar las células endoteliales capilares tumorales (CE). La terapia con dicloruro alfa de radio-223 es el único concepto aprobado para el tratamiento del cáncer con radioisótopos emisores alfa internos. La desintegración de los elementos radiactivos después de alcanzar el tejido maligno libera radiaciones que destruyen los tumores sin causar daños significativos a los tejidos sanos adyacentes. Las radiaciones alfa están muy localizadas y penetran un máximo de 2 a 10 capas celulares. Las células sanas del tejido circundante pueden recuperarse hasta cierto punto de los daños causados por la radiación. Las imágenes nucleares utilizan emisores gamma que tienen una larga vida útil, lo que permite la eliminación de la sangre a medida que el tumor aumenta su absorción del conjugado con el tiempo, mejorando así el contraste. Los agentes de imagen nuclear permiten el diagnóstico de tumores y órganos. Además, el aumento de la conciencia sobre la radioinmunoterapia alfa y el aumento de la disponibilidad de terapias para los procedimientos de tratamiento del cáncer están impulsando la demanda de imágenes nucleares. Por lo tanto, el uso preferido de la radioinmunoterapia alfa en el tratamiento del cáncer está impulsando el crecimiento del mercado de radiofármacos de APAC.
Segmentos de mercado clave
En términos de tipo, el segmento de medicina nuclear de diagnóstico representó la mayor participación del mercado de radiofármacos de APAC en 2020. En términos de aplicación, el segmento de oncología tuvo una mayor participación de mercado del mercado de radiofármacos de APAC en 2020. Además, el segmento de hospitales tuvo una participación mayor en el mercado de radiofármacos de APAC según el usuario final en 2020.
Principales fuentes y empresas incluidas en la lista
Algunas de las principales fuentes primarias y secundarias a las que se hace referencia para preparar este informe sobre el mercado de radiofármacos de APAC son los sitios web de las empresas, los informes anuales, los informes financieros, los documentos del gobierno nacional y las bases de datos estadísticas, entre otros. Las principales empresas que figuran en el informe son Advanced Accelerator Applications; Bayer AG; Bracco Imaging SpA; Cardenal Salud Inc; Curio; ECZACIBA?I MONROL NUCLEAR PRODUCTS CO.; ENERGIA GENERAL; Lantheus Imágenes Médicas, Inc.; Nordión; y RADIOISÓTOPOS NTP.
Informe de razones para comprar
- Comprender el panorama del mercado de radiofármacos de APAC e identificar los segmentos de mercado que tienen más probabilidades de garantizar un fuerte rendimiento
- Manténgase a la vanguardia al comprender el panorama competitivo en constante cambio del mercado de radiofármacos de APAC
- Planifique eficientemente fusiones y adquisiciones y acuerdos de asociación en el mercado de radiofármacos de APAC identificando segmentos de mercado con las ventas probables más prometedoras
- Ayuda a tomar decisiones comerciales informadas a partir de un análisis perspicaz y completo del desempeño del mercado de varios segmentos formar el mercado de radiofármacos de APAC
- Obtener pronóstico de ingresos de mercado para varios segmentos de 2021 a 2028 en la región de APAC.
Segmentación del mercado de radiofármacos de APAC
Mercado de radiofármacos de APAC - Por tipo
- Medicina nuclear de diagnóstico
- SPECT
- PET
- Medicina Nuclear Terapéutica
- Emisores Alfa
- Emisores Beta
- Isótopos de Braquiterapia
- Oncología
- Cardiología
- Neurología
- Otros
Mercado de radiofármacos de APAC - Por usuario final
- Hospitales
- Centros de imágenes
- Centros académicos y de investigación ;
- Otros
Mercado de radiofármacos de APAC: por país
- Japón
- China
- India
- Australia
- Corea del Sur
- Resto de APAC
Mercado de radiofármacos de APAC: perfiles de empresas
- Aplicaciones avanzadas de aceleradores
- Bayer AG
- Bracco Imaging SpA
- Cardinal Health Inc
- Curio
- ECZACIBA?I MONROL NUCLEAR PRODUCTS CO.
- GENERAL ELECTRIC
- Lantheus Medical Imaging, Inc.
- Nordion
- RADIOISÓTOPOS NTP
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 APAC Radiopharmaceuticals Market – By Type
1.3.2 APAC Radiopharmaceuticals Market – By Application
1.3.3 APAC Radiopharmaceuticals Market – By End User
1.3.4 APAC Radiopharmaceuticals Market– By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. APAC Radiopharmaceuticals Market– Market Landscape
4.1 Overview
4.2 APAC PEST Analysis
4.3 Experts Opinion
5. APAC Radiopharmaceuticals Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Surging Use of Alpha Radio Immunotherapy for Cancer Treatment
5.1.2 Escalating Advancements in Nuclear Imaging Techniques
5.2 Market Restraints
5.2.1 Presence of Alternatives
5.3 Market Opportunities
5.3.1 Soaring Growth in Emerging Countries
5.4 Future Trends
5.4.1 Rising Use of Nuclear Medicines for Personalized Treatment
5.5 Impact Analysis
6. Radiopharmaceuticals Market– APAC Analysis
6.1 APAC Radiopharmaceuticals Market Revenue Forecast and Analysis
7. APAC Radiopharmaceuticals Market Analysis – By Type
7.1 Overview
7.2 APAC Radiopharmaceuticals Market Revenue Share, by Type (2021 and 2028)
7.3 Diagnostic Nuclear Medicine
7.3.1 Overview
7.3.2 Diagnostic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.3.3 SPECT
7.3.3.1 Overview
7.3.3.2 SPECT: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.3.4 PET
7.3.4.1 Overview
7.3.4.2 PET: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Therapeutic Nuclear Medicine
7.4.1 Overview
7.4.2 Therapeutic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.3 Alpha Emitters
7.4.3.1 Overview
7.4.3.2 Alpha Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.4 Beta Emitters
7.4.4.1 Overview
7.4.4.2 Beta Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
7.4.5 Brachytherapy Isotopes
7.4.5.1 Overview
7.4.5.2 Brachytherapy Isotopes: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8. APAC Radiopharmaceuticals Market Analysis – By Application
8.1 Overview
8.2 APAC Radiopharmaceuticals Market Revenue Share, by Application (2021 and 2028)
8.3 Oncology
8.3.1 Overview
8.3.2 Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Cardiology
8.4.1 Overview
8.4.2 Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Neurology
8.5.1 Overview
8.5.2 Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9. APAC Radiopharmaceuticals Market Analysis – By End User
9.1 Overview
9.2 APAC Radiopharmaceuticals Market Share, by End User, 2021 and 2028, (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Imaging Centres
9.4.1 Overview
9.4.2 Imaging Centres: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Academic and Research Centers
9.5.1 Overview
9.5.2 Academic and Research Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
10. APAC Radiopharmaceuticals Market – Country Analysis
10.1 APAC: Radiopharmaceuticals Market
10.1.1 Overview
10.1.2 APAC: Radiopharmaceuticals Market, by Country, 2021 & 2028 (%)
10.1.2.1 China: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.1 China: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.1.2 China: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.1.2.1 China: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.1.2.2 China: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.1.3 China: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.1.4 China: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.2 Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.1 Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.2.2 Japan: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.2.2.1 Japan: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.2.2.2 Japan: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.2.3 Japan: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.2.4 Japan: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.3 India: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.1 India: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.3.2 India: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.3.2.1 India: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.3.2.2 India: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.3.3 India: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.3.4 India: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.4 Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.4.1 Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.4.2 Australia: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.4.2.1 Australia: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.4.2.2 Australia: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.4.3 Australia: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.4.4 Australia: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.5 South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.5.1 South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.5.2 South Korea: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.5.2.1 South Korea: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.5.2.2 South Korea: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.5.3 South Korea: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.5.4 South Korea: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
10.1.2.6 Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.6.1 Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
10.1.2.6.2 Rest of APAC: Radiopharmaceuticals Market, By Type, 2019–2028 (USD Million)
10.1.2.6.2.1 Rest of APAC: Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.6.2.2 Rest of APAC: Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine, 2019–2028 (USD Million)
10.1.2.6.3 Rest of APAC: Radiopharmaceuticals Market, by Application, 2019–2028 (USD Million)
10.1.2.6.4 Rest of APAC: Radiopharmaceuticals Market, by End User, 2019–2028 (USD Million)
11. Impact Of COVID-19 Pandemic on APAC Radiopharmaceuticals Market
11.1 APAC: Impact Assessment of COVID-19 Pandemic
12. Industry Landscape
12.1 Overview
12.2 Inorganic Growth Strategies
12.2.1 Overview
12.3 Organic Growth Strategies
12.3.1 Overview
13. Company Profiles
13.1 Cardinal Health Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Curium
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GENERAL ELECTRIC
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Lantheus Medical Imaging, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bayer AG
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Bracco Imaging S.p.A
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 ECZACIBA?I MONROL NUCLEAR PRODUCTS CO.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Nordion
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 NTP RADIOISOTOPES
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Advanced Accelerator Applications
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. APAC Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Table 2. China: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 3. China Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 4. China Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 5. China: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 6. China: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 7. Japan: Radiopharmaceuticals Market, By Type– Revenue and Forecast to 2028 (USD Million)
Table 8. Japan Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 9. Japan Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 10. Japan: Radiopharmaceuticals Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 11. Japan: Radiopharmaceuticals Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 12. India: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 13. India Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 14. India Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 15. India: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 16. India: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 17. Australia: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 18. Australia Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 19. Australia Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 20. Australia: Radiopharmaceuticals Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 21. Australia: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 22. South Korea: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 23. South Korea Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 24. South Korea Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 25. South Korea: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 26. South Korea: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 27. Rest of APAC: Radiopharmaceuticals Market, By Type – Revenue and Forecast to 2028 (USD Million)
Table 28. Rest of APAC Radiopharmaceuticals Market, by Diagnostic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 29. Rest of APAC Radiopharmaceuticals Market, by Therapeutic Nuclear Medicine – Revenue and Forecast to 2028 (USD Million)
Table 30. Rest of APAC: Radiopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 31. Rest of APAC: Radiopharmaceuticals Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 32. Recent Inorganic Growth Strategies
Table 33. Recent Organic Growth Strategies
Table 34. Glossary of Terms
LIST OF FIGURES
Figure 1. APAC Radiopharmaceuticals Market Segmentation
Figure 2. APAC Radiopharmaceuticals Market Segmentation, By Country
Figure 3. APAC Radiopharmaceuticals Market Overview
Figure 4. Diagnostic Nuclear Medicine Segment Held the Largest Share of the Market in 2021
Figure 5. India to Show Significant Growth During Forecast Period
Figure 6. APAC PEST Analysis
Figure 7. APAC Radiopharmaceuticals Market Impact Analysis of Drivers and Restraints
Figure 8. APAC Radiopharmaceuticals Market– Revenue Forecast and Analysis
Figure 9. APAC Radiopharmaceuticals Market Revenue Share, by Type (2021 and 2028)
Figure 10. APAC Diagnostic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. APAC SPECT: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. APAC PET: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. APAC Therapeutic Nuclear Medicine: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. APAC Alpha Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. APAC Beta Emitters: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. APAC Brachytherapy Isotopes: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. APAC Radiopharmaceuticals Market Revenue Share, by Application (2021 and 2028)
Figure 18. APAC Oncology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. APAC Cardiology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. APAC Neurology: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. APAC Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. APAC Radiopharmaceuticals Market Share, by End User, 2021 and 2028 (%)
Figure 23. APAC Hospitals: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. APAC Imaging Centres: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. APAC Academic and Research Centers: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. APAC Others: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. APAC: Radiopharmaceuticals Market, by Key Country – Revenue (2021) (USD Million)
Figure 28. APAC: Radiopharmaceuticals Market, by Country, 2021 & 2028 (%)
Figure 29. China: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 30. Japan: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 31. India: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 32. Australia: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 33. South Korea: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 34. Rest of APAC: Radiopharmaceuticals Market – Revenue and Forecast to 2028 (USD Million)
Figure 35. Impact of COVID-19 Pandemic in APAC Country Markets
- Advanced Accelerator Applications
- Bayer AG
- Bracco Imaging S.p.A
- Cardinal Health Inc
- Curium
- ECZACIBAI MONROL NUCLEAR PRODUCTS CO.
- GENERAL ELECTRIC
- Lantheus Medical Imaging, Inc.
- Nordion
- NTP RADIOISOTOPES
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the APAC radiopharmaceuticals market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the APAC radiopharmaceuticals market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth APAC market trends and outlook coupled with the factors driving the radiopharmaceuticals market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution